This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results- 2Phosphorylation
- 1Alternative splicing
- 1BFABP
- 1Brain fatty acid-binding protein
- 1Brain tumour
- 1Calcineurin
-
Fall 2014
DEAD box protein 1 (DDX1) is a member of the DEAD box family of helicases which bind and unwind double-strand (ds) RNA and are associated with all aspects of RNA metabolism. DDX1 was identified by differential screening of a subtracted cDNA library prepared from two retinoblastoma (RB) cell...
-
Fall 2015
DEAD box proteins are a family of RNA helicases implicated in every aspect of RNA biogenesis and metabolism. Modification of RNA secondary structure by DEAD box proteins has widespread effects on numerous cellular processes due to the ubiquitous nature of RNA. While the biochemical activity of...
-
Spring 2011
The Reelin-Disabled-1 (Dab1) signaling pathway plays a key role in regulating neuronal positioning and synaptic plasticity. Binding of Reelin to its receptors induces tyrosine phosphorylation of the intracellular adaptor protein Dab1. Tyrosine-phosphorylated Dab1 not only rapidly transmits the...
-
Fall 2022
Glioblastoma has a devastating prognosis, and a remarkably low survival rate. Current therapeutic strategies including surgery, radiation and temozolomide are only useful as a palliative therapy, with no significant increase in overall survival. In this study, we investigated multiple therapeutic...
-
Fall 2015
Malignant glioma (MG), comprised of grade III (anaplastic astrocytoma) and grade IV (glioblastoma) astrocytoma, is the most common adult brain tumour, with an incidence of ~4 in 100 000 people. Despite aggressive treatment with surgery, radiation, and chemotherapy, survival remains dismal, with...
-
Fall 2010
Patients diagnosed with malignant glioma tumours have median survivals of 1.6 yrs and 5 months, respectively, highlighting the deadly nature of this disease. Despite aggressive multimodal treatment, patients with malignant glioma often present with secondary brain tumours at sites distal to the...